STABLED Study for Stroke Prevention Reaches Phase 3 Primary Completion

The STABLED study, investigating stroke secondary prevention in patients with non-valvular atrial fibrillation, reached Phase 3 primary completion on 2026-03-31, enrolling 251 participants.

Background

Stroke remains a leading cause of disability and mortality worldwide. A significant proportion of ischemic strokes are attributed to non-valvular atrial fibrillation (NVAF), a common cardiac arrhythmia. Current management often involves anticoagulation, but catheter ablation (CA) has emerged as a potential strategy to reduce stroke risk in NVAF patients. Retrospective studies have suggested a benefit, but the precise risk-benefit profile of CA in NVAF patients who have recently experienced a cerebral infarction has not been thoroughly investigated in prospective randomized trials. The STABLED study aims to address this critical knowledge gap.

Trial design

The STABLED study is a Phase 3 trial that has completed its primary data collection. It enrolled 251 participants to investigate stroke secondary prevention in patients with Ischemic Stroke and Atrial Fibrillation Non-Rheumatic. The trial's objective, as outlined in its summary, is to elucidate the risk and benefit of catheter ablation in non-valvular atrial fibrillation patients with recent cerebral infarction, an area where prospective randomized trial data has been limited.

What this means

The primary completion of the STABLED study signifies a major milestone in its progress. While specific results are not yet available, the completion of primary data collection for this Phase 3 trial means that the data will now be analyzed to determine the efficacy and safety of catheter ablation and edoxaban for secondary stroke prevention in patients with non-valvular atrial fibrillation who have recently experienced an ischemic stroke. The findings are anticipated to provide crucial evidence for clinical decision-making in this high-risk patient population.

Source

Information regarding the primary completion of this trial was sourced from ClinicalTrials.gov, a public registry of clinical studies. The record for study NCT03777631, titled "STroke Secondary Prevention With Catheter ABLation and EDoxaban for Patients With Non-valvular Atrial Fibrillation: STABLED Study", was updated to reflect primary completion on 2026-03-31 on clinicaltrials.gov.